AU2011323078B2 - Compositions and methods for nanopolymer-based nucleic acid delivery - Google Patents

Compositions and methods for nanopolymer-based nucleic acid delivery Download PDF

Info

Publication number
AU2011323078B2
AU2011323078B2 AU2011323078A AU2011323078A AU2011323078B2 AU 2011323078 B2 AU2011323078 B2 AU 2011323078B2 AU 2011323078 A AU2011323078 A AU 2011323078A AU 2011323078 A AU2011323078 A AU 2011323078A AU 2011323078 B2 AU2011323078 B2 AU 2011323078B2
Authority
AU
Australia
Prior art keywords
nucleic acid
poly
acetylglucosamine
deacetylated
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011323078A
Other languages
English (en)
Other versions
AU2011323078A1 (en
Inventor
Marina V. Demcheva
John N. Vournakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Priority to AU2013203247A priority Critical patent/AU2013203247A1/en
Publication of AU2011323078A1 publication Critical patent/AU2011323078A1/en
Priority to AU2016201640A priority patent/AU2016201640A1/en
Application granted granted Critical
Publication of AU2011323078B2 publication Critical patent/AU2011323078B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2011323078A 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery Ceased AU2011323078B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013203247A AU2013203247A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2013203247A Division AU2013203247A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A Division AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (2)

Publication Number Publication Date
AU2011323078A1 AU2011323078A1 (en) 2013-05-02
AU2011323078B2 true AU2011323078B2 (en) 2016-04-14

Family

ID=46025153

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2011323078A Ceased AU2011323078B2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2013203247A Abandoned AU2013203247A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A Abandoned AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2013203247A Abandoned AU2013203247A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A Abandoned AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2011323078B2 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) * 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response

Also Published As

Publication number Publication date
AU2016201640A1 (en) 2016-04-07
ES2763432T3 (es) 2020-05-28
CN108743562A (zh) 2018-11-06
AU2011323078A1 (en) 2013-05-02
WO2012061803A3 (en) 2012-08-16
EP2635261A2 (en) 2013-09-11
US20170128382A1 (en) 2017-05-11
US20130287853A1 (en) 2013-10-31
IL226170A0 (en) 2013-07-31
US20230157971A1 (en) 2023-05-25
CA2816999A1 (en) 2012-05-10
EP2635261A4 (en) 2014-09-17
MX358050B (es) 2018-08-03
JP2016164181A (ja) 2016-09-08
AU2013203247A1 (en) 2013-05-09
MX2013005016A (es) 2014-03-12
JP6029591B2 (ja) 2016-11-24
JP2014500250A (ja) 2014-01-09
CN103282024A (zh) 2013-09-04
EP2635261B1 (en) 2019-10-23
IL226170B (en) 2018-11-29
WO2012061803A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
JP6827488B2 (ja) 鼻内送達のための方法および組成物
US12442005B2 (en) Artificial nucleic acid molecules for improved protein expression
ES2467678T3 (es) Modificación del ARN, que produce unas estabilidad de transcripción y eficiencia de traducción aumentadas
Zhao et al. Enhancing mucosal immune response of Newcastle disease virus DNA vaccine using N-2-hydroxypropyl trimethylammonium chloride chitosan and N, O-carboxymethyl chitosan nanoparticles as delivery carrier
Kutzler et al. DNA vaccines: ready for prime time?
Zhang et al. Polymers for DNA vaccine delivery
Běláková et al. DNA vaccines: are they still just a powerful tool for the future?
Lin et al. Induction of robust immune responses by CpG-ODN-loaded hollow polymeric nanoparticles for antiviral and vaccine applications in chickens
EP2022853A1 (en) Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof
Moore et al. Injectable, ribbon-like microconfetti biopolymer platform for vaccine applications
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
Sun et al. Distribution characteristics of DNA vaccine encoded with glycoprotein C from Anatid herpesvirus 1 with chitosan and liposome as deliver carrier in ducks
Wusiman et al. Poly (lactic-co-glycolic acid) nanoparticle-based vaccines delivery systems as a novel adjuvant for H9N2 antigen enhance immune responses
US20220145309A1 (en) Yeast-Based Oral Vaccination
Jones et al. Biomaterials at the interface of nano-and micro-scale vector–cellular interactions in genetic vaccine design
Fando et al. DNA vaccine technologies: design and delivery
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
WO2024128201A1 (ja) ｍＲＮＡワクチン
CN120586073A (zh) DOTAP-CL修饰的脂质纳米颗粒及其在递送mRNA疫苗中的应用
Heuking et al. Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy
Te-hui et al. Gene Delivery Using Physical Methods
Zhang Development of liver suction-mediated naked plasmid DNA delivery system for in vivo gene therapy
HK40004174A (en) Trans-replicating rna

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired